Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody

Sally J. Denardo, Lois F. O'Grady, Carol M Richman, Desiree S. Goldstein, Robert T O'Donnell, Diane A. Denardo, Linda A. Kroger, Kathleen R. Lamborn, Karl Erik Hellström, Ingegerd Hellström, Gerald L Denardo

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


Background: The biologically active anti-adenocarcinoma monoclonal antibody chimeric L6 (ChL6) was labelled with 131I and administered in cycles to patients with metastatic breast cancer who had failed standard therapy. The therapeutic potential, tumor targeting and maximum tolerated dose of 131I-ChL6 were studied. Methods: Ten patients with L6 reactive breast cancer received an imaging dose of 131I-ChL6 followed 24 hours later by a therapy dose of 131I-ChL6 (20-70mCi/m2). Patients received up to 4 monthly cycles unless they had significant myelosuppression, progression of disease or a high human anti-mouse antibody titer. In vivo activation of effector cell function, complement levels and cytokine release were studied. Results: All 10 patients had detectable cancer on the imaging study. In 7 patients with superficial cancer the radiation dose was 120 to 3700 cGY\cycle; 5-30 times higher than the whole body dose. Therapy resulted in minimal acute or subacute. Dose limiting toxicities were neutropenia and thrombocytopenia. Six of 10 patients had clinical measurable tumor responses; 5 had responses that lasted more than one month (1.5 - 5 months). The MTD for 131I-ChL6, given in at least two monthly doses was 60mCi/m2. Conclusion: Objective clinical responses were seen in five of 10 patients treated with 131I-ChL6. The tumor response in heavily pretreated, advanced breast cancer may be related to the combined effects of targeted radiation and the biological activity of L6/ChL6.

Original languageEnglish (US)
Pages (from-to)1745-1751
Number of pages7
JournalAnticancer Research
Issue number3 B
StatePublished - 1997


  • Antibody
  • Breast cancer
  • ChL6
  • L6
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody'. Together they form a unique fingerprint.

Cite this